Enhancing survival of photoreceptor cells in vivo using the synthetic progestin Norgestrel
- PMID:21689103
- DOI: 10.1111/j.1471-4159.2011.07354.x
Enhancing survival of photoreceptor cells in vivo using the synthetic progestin Norgestrel
Abstract
Retinal degenerations such as Retinitis Pigmentosa remain difficult to treat given the diverse array of genes responsible for their aetiology. Rather than concentrate on specific genes, our focus is on identifying therapeutic avenues for the treatment of retinal disease that target general survival mechanisms or pathways. Norgestrel is a synthetic progestin commonly used in hormonal contraception. Here, we report a novel anti-apoptotic role for Norgestrel in diseased mouse retinas in vivo. Dosing with Norgestrel protects photoreceptor cells from undergoing apoptosis in two distinct models of retinal degeneration; the light damage model and the Pde6b(rd10) model. Photoreceptor rescue was assessed by analysis of cell number, structural integrity and function. Improvements in cell survival of up to 70% were achieved in both disease models, indicating that apoptosis had been halted or at least delayed. A speculative mechanism of action for Norgestrel involves activation of survival pathways in the retina. Indeed, Norgestrel increases the expression of basic fibroblast growth factor which is known to both promote cell survival and inhibit apoptosis. In summary, our results demonstrate significant protection of photoreceptor cells which may be attributed to Norgestrel mediated activation of endogenous survival pathways within the retina.
© 2011 The Authors. Journal of Neurochemistry © 2011 International Society for Neurochemistry.
Similar articles
- The synthetic progesterone Norgestrel is neuroprotective in stressed photoreceptor-like cells and retinal explants, mediating its effects via basic fibroblast growth factor, protein kinase A and glycogen synthase kinase 3β signalling.Wyse Jackson AC, Cotter TG.Wyse Jackson AC, et al.Eur J Neurosci. 2016 Apr;43(7):899-911. doi: 10.1111/ejn.13166. Epub 2016 Feb 11.Eur J Neurosci. 2016.PMID:26750157
- Activation of survival pathways in the degenerating retina of rd10 mice.Samardzija M, Wariwoda H, Imsand C, Huber P, Heynen SR, Gubler A, Grimm C.Samardzija M, et al.Exp Eye Res. 2012 Jun;99:17-26. doi: 10.1016/j.exer.2012.04.004. Epub 2012 Apr 21.Exp Eye Res. 2012.PMID:22546314
- Basic fibroblast growth factor-induced protection from light damage in the mouse retina in vivo.O'Driscoll C, O'Connor J, O'Brien CJ, Cotter TG.O'Driscoll C, et al.J Neurochem. 2008 Apr;105(2):524-36. doi: 10.1111/j.1471-4159.2007.05189.x. Epub 2007 Dec 13.J Neurochem. 2008.PMID:18088352
- Molecular mechanisms of light-induced photoreceptor apoptosis and neuroprotection for retinal degeneration.Wenzel A, Grimm C, Samardzija M, Remé CE.Wenzel A, et al.Prog Retin Eye Res. 2005 Mar;24(2):275-306. doi: 10.1016/j.preteyeres.2004.08.002. Epub 2004 Nov 11.Prog Retin Eye Res. 2005.PMID:15610977Review.
- On the role of CNTF as a potential therapy for retinal degeneration: Dr. Jekyll or Mr. Hyde?Beltran WA.Beltran WA.Adv Exp Med Biol. 2008;613:45-51. doi: 10.1007/978-0-387-74904-4_4.Adv Exp Med Biol. 2008.PMID:18188927Review.No abstract available.
Cited by
- Neuroprotective strategies for retinal disease.Pardue MT, Allen RS.Pardue MT, et al.Prog Retin Eye Res. 2018 Jul;65:50-76. doi: 10.1016/j.preteyeres.2018.02.002. Epub 2018 Feb 23.Prog Retin Eye Res. 2018.PMID:29481975Free PMC article.Review.
- Differential distribution of steroid hormone signaling networks in the human choroid-retinal pigment epithelial complex.Galindez SM, Keightley A, Koulen P.Galindez SM, et al.BMC Ophthalmol. 2022 Oct 20;22(1):406. doi: 10.1186/s12886-022-02585-7.BMC Ophthalmol. 2022.PMID:36266625Free PMC article.
- Progesterone treatment shows greater protection in brain vs. retina in a rat model of middle cerebral artery occlusion: Progesterone receptor levels may play an important role.Allen RS, Sayeed I, Oumarbaeva Y, Morrison KC, Choi PH, Pardue MT, Stein DG.Allen RS, et al.Restor Neurol Neurosci. 2016 Nov 22;34(6):947-963. doi: 10.3233/RNN-160672.Restor Neurol Neurosci. 2016.PMID:27802245Free PMC article.
- Innovation in the Development of Synthetic and Natural Ocular Drug Delivery Systems for Eye Diseases Treatment: Focusing on Drug-Loaded Ocular Inserts, Contacts, and Intraocular Lenses.Pelusi L, Mandatori D, Mastropasqua L, Agnifili L, Allegretti M, Nubile M, Pandolfi A.Pelusi L, et al.Pharmaceutics. 2023 Feb 13;15(2):625. doi: 10.3390/pharmaceutics15020625.Pharmaceutics. 2023.PMID:36839947Free PMC article.Review.
- Age-dependent changes on fractalkine forms and their contribution to neurodegenerative diseases.Eugenín J, Eugenín-von Bernhardi L, von Bernhardi R.Eugenín J, et al.Front Mol Neurosci. 2023 Sep 25;16:1249320. doi: 10.3389/fnmol.2023.1249320. eCollection 2023.Front Mol Neurosci. 2023.PMID:37818457Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources